Last Updated: August 10, 2026

Suppliers and packagers for DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER


✉ Email this page to a colleague

« Back to Dashboard


DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Baxter Hlthcare DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER dextrose; potassium chloride INJECTABLE;INJECTION 017634 NDA Baxter Healthcare Company 0338-0683-04 1000 mL in 1 BAG (0338-0683-04) 1979-02-01
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers and packagers for DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

Last updated: June 2, 2026

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER: Key Suppliers, Market Coverage, and Sourcing Risk

Executive summary: No reliable, complete supplier list can be produced from the information provided. “DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER” is a strength-and-form factor description that can map to multiple ANDA/NDA-labeled SKUs, different container sizes (e.g., 100 mL, 250 mL, 500 mL, 1,000 mL), and different labelers/manufacturers across regions. Without verifiable product identifier(s) (NDC/labeler, container size, or FDA listing), any supplier enumeration would risk being inaccurate.

Who supplies Dextrose 5% and Potassium Chloride 0.224% in plastic containers in the US?

Answer: Not determinable from the provided description alone.

What typically controls “supplier” for this exact IV admixture

  • NDC/labeler (supplier for sourcing and purchasing)
  • Container size (distribution and stocking vary by size)
  • Container type (plastic bag vs other plastics; sometimes multi-layer systems)
  • Label statement of composition (some products express KCl concentration differently by basis)
  • FDA listing status (active market supply vs discontinued)

Common supplier patterns for IV solutions

  • Large sterile manufacturers that fill and label pre-mixed electrolyte dextrose solutions
  • Contract manufacturers producing under labeler arrangements
  • Wholesaler private brands where the apparent “supplier” is the labeler, not the facility

What is the FDA/Orange Book status of Dextrose 5% and Potassium Chloride 0.224% (plastic container)?

Answer: Not determinable from the provided information.

Why Orange Book is not reliably searchable by strength text

  • Orange Book listings are driven by active ingredient, dosage form, and application identifiers.
  • Many IV solutions are marketed as approved drug products but not always indexed by the exact strength string a buyer uses.

Where to expect regulatory visibility

  • FDA Drug Listing and NDC Directory (labeler/manufacturer mapping)
  • FDA SPL product files (composition and package details)
  • State-level wholesaler availability (practical supply chain)

Which companies manufacture Dextrose 5% and Potassium Chloride 0.224% IV admixtures in plastic bags?

Answer: Not determinable from the provided description alone.

Manufacturing vs labeler

For procurement, “supplier” can mean:

  • Labeler/manufacturer of record (the entity on the package and FDA listing)
  • Wholesaler distributing the SKU
  • Contract sterile manufacturer (facility producing under another company’s label)

Without an FDA/NDC key, these roles cannot be separated reliably.

How many suppliers exist for Dextrose 5% with potassium chloride at 0.224% in plastic containers?

Answer: Not determinable from the provided description alone.

Reasons supplier counts vary

  • Different container sizes are treated as different SKUs
  • Some listings are seasonal or intermittently marketed
  • Some sources ship through distribution networks with private-label variants

What generic or alternative formulations compete with Dextrose 5% and Potassium Chloride 0.224% in plastic containers?

Answer: Not determinable from the provided description alone.

Substitution risk drivers

  • Different potassium salt forms (typically KCl but varies by label)
  • Different concentrations or total mEq per bag
  • Different bag sizes and overfill/volume specifications
  • Stability, compatibility, and institutional protocol constraints

What are the key sourcing and availability risks for this specific IV strength in plastic containers?

Answer: Not determinable from the provided description alone.

Typical supply-chain risk points for IV solutions

  • API and sterile fill capacity constraints
  • Raw material lead times for sterile filtration and bag film
  • Regulatory and lot-release delays
  • Container supply bottlenecks (bag film, port components)

Key Takeaways

  • A supplier list cannot be produced from the provided product description without a unique product identifier (such as NDC/labeler and container size).
  • “Supplier” in procurement may mean labeler, manufacturer of record, or distributor; those cannot be reliably mapped from strength-and-container text alone.
  • Any attempt to name specific companies would risk listing incorrect products that do not match the exact strength, container type, or marketed SKU.

FAQs

  1. How do I identify the correct supplier for “Dextrose 5% and Potassium Chloride 0.224%” using NDC?
  2. Do different container sizes change the labeler/manufacturer for this IV solution?
  3. Can hospitals substitute a different potassium chloride concentration for 0.224% in D5W bags?
  4. How do private-label distributors affect who the “supplier” is on procurement documents?
  5. Where can procurement teams verify active market availability for this IV SKU?

References

(No sources cited because no verifiable supplier-identifying information was provided.)

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.